Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SCSCYNEXIS, Inc. logo

SCYNEXIS, Inc. (SCYX)

NASDAQ · Currency in USD
$3.79 ▼ -0.03 (-0.66%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.79 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$3.81
Open
$3.74
Day's Range
$3.71 – $3.84
52 Week Range
$3.53 – $9.12
Volume
54,998
Avg. Volume
225,257
Market Cap
$23.80M
Beta (5Y Monthly)
1.06
PE Ratio (TTM)
--
EPS (TTM)
-$0.87
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: SCYNEXIS, Inc.

Sector
Healthcare
Industry
Medical - Pharmaceuticals
Full-time employees
18
CEO
David Angulo

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.72 · Revenue est. $130.50K
DateEst.Actual
Aug 10, 2026-$0.51$0.63Beat
May 11, 2026-$0.80-$3.36Miss
Mar 4, 2026$1.01$2.00Beat
Nov 5, 2025-$1.60-$1.36Beat
Aug 14, 2025-$1.52-$1.12Beat
May 16, 2025-$1.55-$0.88Beat

Analyst view

Rating: Buy
Buy 93% · Hold 7% · Sell -0%

Get free alerts on SCYX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.